ArticlePregnancy (Hoboken, N.J.)2025
Characterizing longitudinal blood pressure trajectories in patients at high risk for de novo postpartum hypertension: A randomized controlled trial secondary analysis.
Article in Pregnancy (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protocol for Monitoring Postpartum Hypertension Outcomes via a Smartphone App (MOMitor): Ecological Momentary Assessment.JMIR research protocols · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Introduction: De novo postpartum hypertension (dnPPHTN), defined as new-onset high blood pressure (BP) after delivery in individuals who were normotensive through pregnancy and delivery, accounts for up to two-thirds of postpartum hypertension cases. Despite its prevalence, there is limited knowledge of BP trends in the postpartum period, hindering opportunities for early detection and timely intervention for dnPPHTN. This study aimed to characterize longitudinal postpartum BP patterns in patients at high risk for dnPPHTN. Methods: This secondary analysis utilized data from a negative randomized controlled trial (PMID: 38641089) involving 82 normotensive patients at high risk for dnPPHTN, who were randomized to receive either a 5-day course of 20 mg oral furosemide or placebo starting from postpartum day 1. BPs were monitored every 4-8 h from delivery to discharge, and subsequently via Bluetooth-enabled remote monitoring twice daily for 6 weeks. The primary goal of this secondary analysis was to characterize distinct patterns of longitudinal BP trajectories in the placebo group. Secondary goals included exploring differences in early postpartum BP trends between those who developed dnPPHTN and those who remained normotensive, as well as identifying the timing of peak BPs. Trends were assessed graphically using local polynomial regression fitting. Linear mixed-effects models were used to examine temporal BP trajectories, including random intercepts and slopes, with an interaction term for the time trend and dnPPHTN diagnosis to explore differential impacts. Results: A total of 40 participants from the placebo arm of the parent trial were included, contributing a total of 2235 postpartum BP measurements. Both systolic BP (SBP) and diastolic BP (DBP) increased until postpartum days 9 and 12, respectively, before subsequently declining. Significant differences in BP trajectories were observed between participants who developed dnPPHTN ( Conclusion: Using remote monitoring technology, we characterized distinct postpartum BP trajectories in patients at risk for dnPPHTN, revealing a prolonged rise into the second postpartum week and trends that distinguish physiologic from pathophysiologic BP changes. These findings suggest that extended postpartum BP monitoring may be important for timely identification and intervention in patients developing dnPPHTN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.